DARE

$1.45

Post-MarketAs of Mar 17, 8:00 PM UTC

Daré Bioscience, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.45
Potential Upside
5%
Whystock Fair Value$1.52
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the tre...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-2543.13%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.10

Recent News

Zacks
Mar 9, 2026

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 2, 2026

uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 20, 2026

Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 14, 2025

Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...

Dare Bioscience Inc (DARE) outlines its innovative pipeline progress and financial fortification, while navigating regulatory hurdles and market expansion plans.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 13, 2025

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.